Cost-Effectiveness Analysis of Nirsevimab for Respiratory Syncytial Virus Disease Prevention in Newborns of Hong Kong [0.03%]
香港新生儿防治呼吸道合胞病毒疾病的奈西利马布成本效益分析
Yingcheng Wang,Mingjun Rui,Qiran Wei et al.
Yingcheng Wang et al.
Background: Nirsevimab, a long-acting monoclonal antibody, was shown to prevent respiratory syncytial virus (RSV) infections in newborns. We evaluated the cost-effectiveness of nirsevimab strategies for newborns from the ...
Absences, Symptoms and Respiratory Viruses in a Swiss School: Longitudinal Study With Serial Saliva Sampling [0.03%]
瑞士一所学校中儿童缺课、症状与呼吸道病毒的纵向研究：连续采集唾液标本的研究
Nicolas Banholzer,David Kronthaler,Pascal Bittel et al.
Nicolas Banholzer et al.
Background: Viral respiratory infections contribute to sick days in school children. We monitored respiratory infections, absences, and symptoms in a Swiss school. ...
First Detection of Boosepivirus B1 in a Sick Yearling's Nasal Swab, Mexico [0.03%]
墨西哥病犊鼻拭子中首次检测到Boosepi病毒B1型
Judith U Oguzie,Gustavo Hernandez-Vidal,Gustavo Moreno-Degollado et al.
Judith U Oguzie et al.
Establishing Epidemic and Intensity Thresholds After a Major Change in Respiratory Virus Surveillance in Spain in 2020 [0.03%]
西班牙在2020年进行重大呼吸道病毒监测变更后的疫情和强度阈值的建立
Ana María Puerto,José Eugenio Lozano,Marcos Lozano et al.
Ana María Puerto et al.
Objectives: We estimated acute respiratory infections (ARIs) and influenza-like illness (ILI) thresholds for SiVIRA, a new integrated surveillance system set up in Spain in 2020. ...
Prevalence of Resistance-Associated Mutations in RSV F Protein Against Monoclonal Antibodies Prior to Widespread Implementation: Findings From a Prospective German Pediatric Cohort [0.03%]
德国儿科前瞻性队列中广泛实施前RSV F蛋白单克隆抗体抗性相关突变的流行率
Martin Wetzke,Duyen Bao Le,Inga Tometten et al.
Martin Wetzke et al.
Background: The emergence of resistance-associated substitutions in RSV against novel monoclonal antibodies is a concern given widespread prophylactic use. ...
The National Burden of Influenza-Associated Respiratory Illness Among Children Aged [0.03%]
我国流感相关呼吸道疾病在儿童中的负担分析
Adamou Lagare,William W Davis,Neha N Patel et al.
Adamou Lagare et al.
Background: Influenza contributes substantially to severe acute respiratory infection (SARI) morbidity and mortality worldwide. However, few countries have estimated influenza disease burden, especially middle and low-inc...
Effectiveness and Impact of Autumn 2023 COVID-19 Vaccination in Preventing Hospitalizations in Navarre, Spain, October 2023 to September 2024 [0.03%]
西班牙纳瓦拉地区2023年秋季新冠疫苗接种在预防住院方面的有效性和影响：2023年10月至2024年9月
Iván Martínez-Baz,Camino Trobajo-Sanmartín,Miguel Fernández-Huerta et al.
Iván Martínez-Baz et al.
Objective: We aimed to estimate autumn 2023 COVID-19 vaccine effectiveness (CVE) in preventing hospitalizations due to COVID-19 until September 2024. Meth...
Host Immune Response to Respiratory Syncytial Virus Infection in Children [0.03%]
儿童呼吸道合胞病毒感染的宿主免疫反应
Gang Chen,Xiuchang Ma,Jinhuan Wu et al.
Gang Chen et al.
Respiratory syncytial virus (RSV) is one of the leading causes of severe respiratory diseases in children, especially in infants. The immune responses induced by RSV infection are a fairly complex process that can contribute significantly t...
Influenza Vaccine Effectiveness During the 2023/2024 Season: A Test-Negative Case-Control Study Among Emergency Hospital Admissions With Respiratory Conditions in Northern Ireland [0.03%]
2023/2024季节流感疫苗效力：北爱尔兰急诊病房呼吸道疾病患者中的病例对照研究
Magda Bucholc,Mark G O&#x;Doherty,Declan T Bradley
Magda Bucholc
Background: We evaluated the effectiveness of the influenza vaccine programme against infection among emergency hospital admissions with respiratory conditions in Northern Ireland during the 2023/2024 influenza season. ...
Update on H5N1 Panzootic: Infected Mammal Species Increase by Almost 50% in Just Over a Year [0.03%]
H5N1禽流感疫情进展：一年多来感染哺乳动物种类增加近50%
Pablo Plaza,Sergio A Lambertucci
Pablo Plaza